The mean of analysts' price targets for Arcturus Therapeutics (ARCT) points to a 371.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement ...

Fintel reports that on May 28, 2025, Scotiabank initiated coverage of Arcturus Therapeutics Holdings (NasdaqGM:ARCT) with a ...

Arcturus And The Struggle For Substantive Justice. Legal News and Analysis - India - Intellectual Property - Conventus Law ...

About Arcturus Therapeutics Holdings Inc. Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious ...

Detailed price information for Vigil Neuroscience Inc (VIGL-Q) from The Globe and Mail including charting and trades.

Crispr Therapeutics said it is partnering with Sirius Therapeutics to develop and commercialize SRSD107, a small interfering RNA therapy to treat thromboembolic disorders. Under the agreement ...

Check Out Our Latest Report on Arcturus Therapeutics Arcturus Therapeutics Price Performance NASDAQ ARCT opened at $11.65 on Thursday. The company has a market cap of $315.96 million, a PE ratio ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its ...